Brain-Derived Neurotrophic Factor and Its Serum Levels in Schizophrenic Patients

Open access


INTRODUCTION: Neurotrophins have an important role in regulating the development and maintenance of the peripheral and central nervous systems’ function. Thus, the neurotrophin hypothesis of schizophrenia has postulated that the changes in the brain of schizophrenic patients are the result of disturbances of developing processes involving these molecules. AIM: We analyse in the present study the changes in the serum levels of brain-derived neurotrophic factor (BDNF) in schizophrenic patients as possible epiphenomena of underlying alterations of the neurotrophic factor in central nervous system, reflecting its role in the pathophysiology of schizophrenia. PATIENTS AND METHODS: Twenty-one schizophrenic patients satisfying the DSM-IV criteria for diagnosis of schizophrenia were enrolled in the study. The control group consisted of 28 age-matched mentally healthy subjects. Serum BDNF levels were determined in patients and normal controls using ELISA (Chemicon International, USA & Canada). The data were analyzed statistically with Student’s t- test in SPSS 9.0. RESULTS: The serum BDNF levels were lower in the schizophrenic patients than in the control subjects, reaching statistically significant difference (t = 2.72, p = 0.009). Female patients had lower serum BDNF levels than the male patients but the difference fell short of statistical significance (t = 0.1, p = 0.9). CONCLUSIONS: The BDNF reduction in serum indicates a potential deficit in neurotrophic factor release in patients with schizophrenia and support the concept that BDNF might be associated with schizophrenia

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Weinberger DR Lipska BK. Cortical maldevelopment antipsychotic drugs and schizophrenia: a search of common ground. Schizophr Res 1995;16:87-110.

  • 2. DeLisi LE. Is schizophrenia a lifetime disorder of brain plasticity growth and aging? Schizophr Res 1997;23:119-29.

  • 3. Bersani G Iannitelli A Fiore M Angelucci F Aloe L. Data and hypotheses on the role of nerve growth factor and other neurotrophins in psychiatric disorders. Med Hypotheses 2000;55:199-207.

  • 4. Thome J Foley P Riederer P. Neurotrophic factors and the maldevelopmental hypothesis of schizophrenic psychoses. Review article. J Neural Transm 1998;105:85-100.

  • 5. Aloe L Iannitelli A Angelucci F Bersani G Fiore M. Studies in animal models and humans suggesting a role of nerve growth factor in schizophrenia-like disorders. Behav Pharmacol 2000;11:235-42.

  • 6. Fiore M Korf J Angelucci F Talamini L Aloe L. Prenatal exposure to methylazoxymethanol acetate in the rat alters neurotrophin levels and behavior: considerations for neurodevelopmental diseases. Physiol Behav 2000;71:57-67.

  • 7. Fiore M Aloe L Westenbroek C Amendola T Antonelli A Korf J. Bromodeoxyuridine and methylazoxymethanol exposure during brain development affects behavior in rats: consideration for a role of NGF and BDNF. Neurosci Lett 2001;309:113-116.

  • 8. Takahashi M Shirakawa O Toyooka K Kitamura N Hashimoto T Maeda K et al. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol Psychiatry 2000;5:293-300.

  • 9. Altar CA DiStefano PS. Neurotrophin trafficking by anterograde transport. Trends Neurosci 1998;21:433-7.

  • 10. Kokaia Z Bengzon J Metsis M Kokaia M Persson H Lindvall O. Coexpression of neurotrophins and their receptors in neurons of the central nervous system. Proc Natl Acad Sci USA 1993;90:6711-15.

  • 11. Chen CC Huang TL. Effects of antipsychotics on the serum BDNF levels in schizophrenia. Psychiatry Res 2011;189(3):327-30.

  • 12. Lee AH Lange C Ricken R Hellweg R Lang UE. Reduced brain-derived neurotrophic factor serum concentrations in acute schizophrenic patients increase during antipsychotic treatment. J Clin Psychopharmacol 2011;31(3):334-6.

  • 13. Martinotti G Ricci V Di Nicola M Caltagirone C Bria P Angelucci F. Brain-derived neurotrophic factor and electroconvulsive therapy in a schizophrenic patient with treatment-resistant paranoidhallucinatory symptoms. J ECT 2011;27(1):44-6.

  • 14. Buckley PF Pillai A Howell KR. Brain-derived neurotrophic factor: fi ndings in schizophrenia. Curr Opin Psychiatry 2011;24(2):122-7.

  • 15. Favalli G Li J Belmonte-de-Abreu P Wong AH Daskalakis ZJ. The role of BDNF in the pathophysiology and treatment of schizophrenia. J Psychiatr Res 2012;46(1):1-11.

  • 16. Toyooka K Asama K Watanabe Y Muratake T Takahashi M Someya T et al. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res 2002;110:249-57.

  • 17. Thompson RM Weickert CS Wyatt E Webster MJ. Decreased BDNF trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders. J Psychiatry Neurosci 2011;36(3):195-203.

  • 18. Vaidya VA Terwilliger RM Duman RS. Role of 5-HT2A receptors in the stress-induced downregulation of brain-derived neurotrophic factor expression in rat hippocampus. Biol Psychiatry 2003;54(1):59-69.

  • 19. Cavus I Duman RS. Infl uence of estradiol stress and 5-HT2A agonist treatment on brain-derived neurotrophic factor expression in female rats. Neurosci Lett 1999;262(1):1-4.

  • 20. Sajatovic M Meltzer HY. The effect of short-term electroconvulsive treatment plus neuroleptics in treatment-resistant schizophrenia and schizoaffective disorder. Convuls Ther 1993;9:167-75.

  • 21. Sotiropoulou M Mantas C Bozidis P Marselos M Mavreas V Hyphantis T Antoniou K. BDNF serum concentrations in fi rst psychotic episode drug-naïve schizophrenic patients: associations with personality and BDNF Val66Met polymorphism. Life Sci 2013;92(4-5):305-10.

Journal information
Impact Factor

CiteScore 2018: 0.587

SCImago Journal Rank (SJR) 2018: 0.311

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 241 82 1
PDF Downloads 109 36 2